Chugai Renews License to EpiVax’s ISPRI In Silico Toolkit for Immunogenicity Assessment
Chugai, one of Japan's leading research-based pharmaceutical companies with strengths in biotechnology products, integrated the advanced ISPRI toolkit into their preclinical assessment pipeline after an extended head-to-head comparison with other in silico tools in September 2013. This 3-year extension will